A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Eisai

Status: Enrolling

Conditions: Biliary Tract Cancer

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT06793709

E7090-M081-501

Details and patient eligibility

About

The primary purpose of this study is to investigate the safety of Tasfygo.

Enrollment: 60 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.

Exclusion criteria

Not applicable.

Trial design

60 participants in 1 patient group

Tasfygo tablet 35 milligrams (mg)

Treatment:

Other: No Intervention